Lipid-mediated intracellular delivery of recombinant bioPROTACs for the rapid degradation of undruggable proteins
Abstract Recently, targeted degradation has emerged as a powerful therapeutic modality. Relying on “event-driven” pharmacology, proteolysis targeting chimeras (PROTACs) can degrade targets and are superior to conventional inhibitors against undruggable proteins. Unfortunately, PROTAC discovery is li...
Main Authors: | Alexander Chan, Rebecca M. Haley, Mohd Altaf Najar, David Gonzalez-Martinez, Lukasz J. Bugaj, George M. Burslem, Michael J. Mitchell, Andrew Tsourkas |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2024-07-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-024-50235-x |
Similar Items
-
A TRIM21-based bioPROTAC highlights the therapeutic benefit of HuR degradation
by: Alice Fletcher, et al.
Published: (2023-11-01) -
Commentary: PROTACs make undruggable targets druggable: Challenge and opportunity
by: Bin Lu, et al.
Published: (2021-10-01) -
BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes
by: Shuiyan Wu, et al.
Published: (2021-04-01) -
Developing drugs for the ‘undruggable’
by: Abigail Sawyer
Published: (2020-10-01) -
Beyond canonical PROTAC: biological targeted protein degradation (bioTPD)
by: Huifang Wang, et al.
Published: (2023-07-01)